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Abstract 
We report the synthesis of a small series of 6”-triazol-1-yl-substituted α-GalCer analogues by 
late-stage conversion of the 6”-OH to an azide group, copper-catalyzed azide-alkyne 
cycloaddition and final deprotection. When evaluated for their capacity to induce IL-2 
secretion in vitro, all compounds proved equally potent or superior to α-GalCer. The S.A.R 
suggests that the improved antigenic activity is mainly triggered by the triazole 
functionalization in se. While the introduction of selected substitutuents at C-4 of this 
heterocyclic ring is tolerated, this generally fails to further improve antigenicity. 
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Introduction 
Invariant natural killer T cells (iNKT cells) are a unique lymphocyte population characterized 
by markers associated with both NK and conventional T cells.
1
 Their semi-invariant T cell 
receptor (TCR) is encoded by an invariant Vα14-Jα18 chain in mice (homologous Vα24Jα18 
chain in humans), preferentially paired with Vβ8.2, Vβ7 or Vβ2 (Vβ11 in humans). 
Recognition of glycolipid antigens presented by the MHC class I-like protein CD1d and 
subsequent activation of these iNKT cells lead to a rapid release of copious amounts of 
proinflammatory and regulatory cytokines, including IFN-γ and IL-4. Hence they contribute 
to different immune responses against microorganisms,
2
 tumors
3
 and self-antigens.
4
 Since 
iNKT cells bridge the innate and adaptive immune system, they represent an attractive target 
for immunotherapeutics. 
The most extensively studied ligand for iNKT cells is KRN7000 (1, Figure 1), also referred to 
as α-galactosylceramide (α-GalCer), a structurally optimized compound derived from extracts 
of the marine sponge Agelas Mauritianus.
5
 Its potential in the treatment of several diseases 
such as certain tumors, infections and autoimmune diseases has been related to the activation 
of iNKT cells
6
 and downstream activation of other immune cells such as NK
7
 and B cells.
8
 
However, the opposing activities of the simultaneous secreted Th1 and Th2 cytokines are 
considered a major limitation for the therapeutic applications of α-GalCer.9 For that reason, a 
lot of effort has been investigated in the search for potent α-GalCer analogues with a biased 
Th1 or Th2 profile. 
Numerous modifications of all parts of KRN7000, i.e. the galactose, the phytosphingosine and 
the acyl moieties, have been investigated.
10
 This has led to the identification of OCH (2), a 
prototypical Th2 polarizer characterized by a reduced sphingosine chain and a slightly 
shortened acyl chain
11
 and the Th1 polarizing α-C-GalCer (3), in which the O-anomeric link 
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is replaced by a CH2 group.
12
 S.A.R. studies revealed a wide variety of possible alterations in 
the ceramide part resulting in a shifted cytokine profile. By contrast, successful modifications 
of the galactose moiety are rather scarce and mostly limited to the 6”-position. 6”-
modifications were first reported by the group of Savage, who showed that analogues 
containing different fluorophores
13
 or an acetamide group
14
 at this position were still able to 
activate iNKT cells similar to α-GalCer. This finding led different groups to explore 
alternative C-6”-modifications such as pegylation,15 O-methylation (RCAI-6) and 6”-
deoxygenation.
16
 Previously, we demonstrated that a C-6”-naphthylurea derivative (NU-α-
GalCer, 4) exhibits marked anti-tumor effects in a mouse B16 melanoma model.
17
 A crystal 
structure of NU-α-GalCer complexed to CD1d and the TCR allowed relating this response to 
the induction of a third anchor in CD1d by the naphthylurea group, thereby probably 
enhancing the affinity for CD1d. Encouraged by these findings, we decided to investigate 
alternative C-6”-modifications. Here, we describe the synthesis and preliminary biological 
evaluation of a small series of α-GalCer derivatives containing different 4-substituted triazol-
1-yl moieties at the C-6”-position. 
 
Figure 1. Structures of KRN7000, OCH, α-C-GalCer and NU-α-GalCer and PhA- α-GalCer. 
The copper-catalyzed azide–alkyne cycloaddition (CuAAC) variant of Huisgen’s 1,3-dipolar 
cycloaddition provides an easy and reliable method to link two building blocks via a 1,2,3-
triazole moiety. Besides being a rigid linking unit, the 1,4-disubstituted triazole also possesses 
desirable pharmacological properties.
18
 It is metabolically stable and, due to its high aromatic 
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stabilization, resistant towards acid and basic hydrolysis and towards reductive and oxidation 
conditions. It has a large dipole moment (about 5 D) and is able to participate in hydrogen 
bond formation, dipole-dipole and π-stacking interactions. Since the aforementioned crystal 
structure revealed an extra hydrogen bond between the urea carbonyl oxygen of NU-α-GalCer 
and Thr159 of CD1d, the capacity of a triazole moiety to act as H-bonding acceptor is most 
appealing. Moreover, a 1,4-disubstituted triazole group is suggested as a bioisostere of a 
trans-amide bond, which is interesting in view of the distinct Th1 profile of α-GalCer 
analogues with aromatic amides on C-6” such as phenyl-substituted amide 5.19 Hence, its 
corresponding triazole compound 9c is synthesized and evaluated for comparative reasons. 
Finally, a docking experiment of C-6”-(1,2,3-triazol-1-yl)-substituted α-GalCer (9a) in the 
structure of the ternary complex indicates that introduction of aromatic substituents in 
position 4 of the triazole ring might favorably occupy the cleft that accommodates the 
naphthyl group of NU-α-GalCer (Figure 2). Hence, such aromatic substituents may induce a 
similar hydrophobic pocket in CD1d. This led us to select a homologous series of aromatic 
alkynes, allowing us to investigate the influence of the linker length between the triazole ring 
and the aromatic group on the iNKT cell activity. 
 
Figure 2. Docking of a 6”-triazole-substituted α-GalCer analogue (green: triazole compound; 
purple: NU-α-GalCer) 
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Incorporation of a triazole unit at the C-6” position has very recently been described by the 
group of Besra for the synthesis of homodimeric α-GalCer analogues.20 Pegylated as well as 
alkylene spacers of varying lengths were used to link the two α-GalCer units. Depending on 
the linker length, the pegylated dimers showed similar or lower iNKT cell stimulation as α-
GalCer. By contrast, the alkylene derivatives were less active and proved to be insensitive to 
the linker length. Prompted by this report and the more recently published 6”-triazole α-
GalCer analogues by the same group,
21
 we want to disclose the synthesis and initial biological 
results of a distinct series of 6”-triazole modified analogues. 
Results and Discussion 
Chemistry 
The synthesis of the desired triazoles started from compound 6 (Scheme 1). We recently used 
this intermediate, which is obtained by regioselective opening of the 4,6-O-benzylidene 
precursor, for the synthesis of galacturonic acid and α-D-fucopyranosyl analogues of 
KRN7000.
22
 Conversion of the primary hydroxyl group to an azide group via a Mitsunobu 
reaction with diphenylphosphorazidate (DPPA) afforded compound 7 in excellent yield. 
Initial attempts to convert 7 to triazole 8b using a CuAAC reaction at ambient temperature did 
not result in triazole formation, even after 48 hours. Based on a report by Carvalho and 
coworkers
23
 and our own lab experiences, we then performed the CuAAC reaction under 
microwave conditions (70 °C) in the presence of the appropriate alkyne, successfully 
obtaining compounds 8b-f in good yields. Due to solubility reasons, DMF was chosen as a 
solvent, rather than common mixtures such as H2O/tBuOH or H2O/THF. Aberrantly, the 
unsubstituted triazole 8a was acquired by treatment with neat vinylacetate (120 °C). This 
procedure provides an improved and simple method compared to other reported alternatives 
such as the use of TMS-acetylene or acetylene gas.
24
 Final debenzylation by a catalytic 
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hydrogenolysis afforded the desired analogues 9a-f in moderate yields. In their recent 
publication, Besra and coworkers synthesized structurally related triazoles by CuAAC on the 
unprotected 6”-azido-6”-deoxy-α-GalCer applying conventional heating. 
  
Scheme 1. Reagents and conditions: (a) Ph3P, DEAD, DPPA, THF, -20 °C, 92%; (b) 
appropriate alkyne, sodium ascorbate, CuSO4, DMF, μW (70-120 °C, 250 W), 60%-97%; (c) 
Pd black, H2, EtOH/CHCl3, 22%-53%. 
Biological Evaluation 
To assess the antigenic activity of the final compounds, bone marrow dendritic cells 
(BMDCs) were loaded during 20 hours with 100 ng/mL glycolipid. After 16 hours of 
coculture with 2C12 cells (iNKT cell hybridoma), IL-2 secretion was determined by ELISA. 
9a-f showed an efficacy to release IL-2 that was higher or comparable to α-GalCer (Figure 3). 
The analogues in which a butyl (9b) or phenyl (9c) substitituent is directly attached to the 
triazole ring tend to induce the highest IL-2 secretion. Strikingly, the response of phenyl-
substituted triazole 9c contrasts with the in vitro results obtained by Besra and co-workers, 
where a remarkably reduced iNKT cell stimulatory activity is observed for this compound.
21
 
A possible explanation for this discrepancy is the direct incubation of glycolipids, BMDCs 
and iNKT cell hybridomas in their assay, while we used glycolipid-loaded BMDCs. 
Introduction of varying linker lengths between the triazole and the phenyl moieties doesn’t 
seem to significantly influence the antigenic activity. Hence we speculated that the mere 
presence of a triazol-1-yl ring at position 6” suffices to cause a superior antigenic activity than 
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α-GalCer. Affirmatively, dendritic cells (DCs) loaded with the unsubstituted triazole analogue 
9a were even better in stimulating iNKT cells to release IL-2. This is consistent with the 
potent iNKT cell activity of the precursor azide reported in the publication of Besra and co-
workers.
21
 The IL-2 secretion induced by butyl containing analogue 9b is in line with the 
alkyl-substituted triazoles of Besra, where the one with an octyl chain is far more active than 
the one with a longer undecyl chain. Contradictory to the docking experiment, however, these 
data indicate that 1,4-substitution of the triazole moiety doesn’t interfere in the interaction 
with CD1d and the TCR, provided that the attached group doesn’t exceed a certain size.  
 
Figure 3. IL-2 secretion after coculture of 2C12 cells (iNKT cell hybridoma) with glycolipid 
(100 ng/mL) loaded BMDCs. 
Conclusions 
In summary, a series of phenyl-substituted C-6”-triazolyl α-GalCer analogues as well as a 
butyl- and non-substituted one have been synthesized using a copper-catalyzed azide-alkyne 
cycloaddition reaction. Evaluation of the in vitro IL-2 secretion induced by these compounds 
reveals them as potent iNKT cell stimulating ligands. We suggest that the observed increase 
in antigenic activity is mainly due to the triazole functionalization whereby further 
substitutions at C-4 of this heterocycle with small groups is tolerated.  
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Experimental Section 
Chemical Synthesis 
Precoated Macherey-Nagel SIL G/UV254 plates were used for TLC, and spots were examined 
under UV light at 254 nm and further visualized by sulfuric acid-anisaldehyde spray. Column 
chromatography was performed on Biosolve silica gel (63-200 µm, 60 Å). NMR spectra were 
obtained with a Varian Mercury 300 Spectrometer. Chemical shifts are given in ppm ( ) 
relative to the residual solvent signals, in the case of CDCl3:  = 7.26 ppm for 
1
H and  = 77.4 
ppm for 
13
C and in the case of pyridine-d5:  = 8.74, 7.58 and 7.22 ppm for 
1
H and  = 149.9, 
135.5 and 123.5 ppm for 
13
C. IR spectra were recorded on a Varian Scimitar 800 FT-IR 
spectrometer as KBr pellets. The absorption peaks are reported in cm
-1
. Exact mass 
measurements were performed on a Waters LCT Premier XE TOF equipped with an 
electrospray ionization interface and coupled to a Waters Alliance HPLC system. Samples 
were infused in a in a CH3CN/HCOOH (1000:1) mixture at 10 mL/min.(2S,3S,4R)-3,4-di-O-
benzyl-1-O-(2,3,4-tri-O-benzyl-α-D-galactopyranosyl)-2-hexacosylamino-octadecane-
1,3,4-triol (6). 
IR: 3485, 3319, 3036, 2922, 2851, 1647. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(6-azido-2,3,4-tri-O-benzyl-6-deoxy-α-D-
galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (7). To a solution of 
intermediate 6 (500 mg, 0.38 mmol) and triphenylphosphine (400 mg, 1.53 mmol) in THF (25 
mL) at -20 °C were added DEAD (0.7 mL, 2.2 M) and DPPA (0.33 mL, 1,53 mmol). The 
reaction mixture was stirred overnight and after completion of the reaction, the solvent was 
removed under reduced pressure. Purification by column chromatography (hexanes/EtOAc: 
9/1) resulted in azide 7 (471 mg, 92%) as a white solid. 
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1
H NMR (300 MHz, CDCl3): δ7.42-7.26 (m, 25H, arom. H), 5.87 (d, J = 8,6 Hz, 1H, NH), 
4.98 (d, J = 11.4 Hz, 1H, CH2-Ph), 4.84 (d, J = 3.8 Hz, 1H, H-1”), 4.82-4.72 (m, 4H, CH2-
Ph), 4.64 (d, J = 11.9 Hz, 1H, CH2-Ph), 4.61-4.57 (m, 2H, CH2-Ph), 4.51 (d, J = 11.5 Hz, 1H, 
CH2-Ph), 4.49 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.32-4.24 (m, 1H, H-2), 4.02 (dd, J = 3.5 and 
10.1 Hz, 1H, H-2”), 3.91-3.83 (m, 3H, H-3”, H-1, H-4”), 3.81-3.74 (m, 3H, H-3, H-1, H-5”), 
3.55-3.51 (m, 1H, H-4), 3.47 (dd, J = 8.1 and 12.4 Hz, 1H, H-6”), 2.99 (dd, J = 6.2 and 12.4 
Hz, 1H, H-6”), 2.01-1.85 (m, 2H, COCH2), 1.64-0.98 (m, 72H, CH2), 0.88 (t, J = 6.6 Hz, 6H, 
CH3). 
13
C NMR (75 MHz, CDCl3): δ173.01, 150.14, 150.03, 138.89, 138.78, 138.73, 138.60, 
138.32, 130.30, 130.28, 128.68, 128.66, 128.63, 128.61, 128.57, 128.15, 128.06, 128.04, 
127.97, 127.91, 127.84, 127.77, 127.69, 126.36, 126.34, 120.49, 120.43, 99.34, 80.09, 79.56, 
79.04, 77.66, 77.44, 77.24, 76.81, 75.07, 74.87, 73.68, 73.51, 72.06, 70.25, 69.04, 51.61, 
50.37, 36.98, 32.16, 30.06, 29.96, 29.94, 29.89, 29.84, 29.69, 29.64, 29.61, 29.59, 26.16, 
25.95, 22.92, 14.35. 
IR: 3312, 2978, 2918, 2849, 2097, 1645. Exact mass (ESI-MS) for C85H128N4O8 [M+H]
+
 
found, 1333.9846; calcd, 1333.9805. 
General procedure for CuAAC click reaction 
To a solution of azide 7 (80 mg, 0.06 mmol) in DMF (2 mL)was added the appropriate 
alkyne, sodium ascorbate and copper(II)sulfate. The reaction mixture was stirred for 20 
minutes at 70 °C in the microwave. After extraction with EtOAc, the organic phase was 
washed with brine and dried over Na2SO4, followed by evaporation of the solvent. 
Purification by column chromatography (hexanes/EtOAc: 7.5/2.5) afforded the desired 
triazoles 8b (74%), 8c (60%), 8d (95%), 8e (80%) and 8f (97%) . 
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(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-6-(4-butyltriazol-1-yl)-α-D-
galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (8b). 
1
H NMR (300 MHz, CDCl3): δ7.27-7.03 (m, 26H, arom. H), 5.63 (d, J = 8.5 Hz, 1H, NH), 
4.94 (d, J = 11.1 Hz, 1H, CH2-Ph), 4.78 (d, J = 3.5 Hz, 1H, H-1”), 4.73 (d, J = 11.7 Hz, 1H, 
CH2-Ph), 4.71 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.64 (d, J = 11.7 Hz, 2H, CH2-Ph), 4.57 (d, J = 
11.7 Hz, 1H, CH2-Ph), 4.56 (d, J = 11.1 Hz, 1H, CH2-Ph), 4.48 (d, J = 11.7 Hz, 1H, CH2-Ph), 
4.40 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.39 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.31 (dd, J = 5.9 and 
13.7 Hz, 1H, H-6”), 4.21-4.15 (m, 1H, H-2), 4.12 (dd, J = 5.9 and 13.1 Hz, 1H, H-6”), 4.00-
3.96 (m, 2H, H-2”, H-5”), 3.80 (dd, J = 2.6 and 10.2 Hz, 1H, H-3”), 3.68-3.59 (m, 3H, H-4”, 
H-3, H-1), 3.52-3.41 (m, 2H, H-1, H-4), 2.57 (app. t, J = 7.7 Hz, 2H, CH2), 1.88-1.71 (m, 2H, 
COCH2), 1.56-1.05 (m, 72H, CH2), 0.84 (t, J = 7.3 Hz, 3H, CH3), 0.81 (t, J = 6.8 Hz, 6H, 
CH3). 
13
C NMR (75 MHz, CDCl3): δ173.01, 148.40, 138.82, 138.77, 138.56, 138.49, 138.44, 
128.76, 128.68, 128.65, 128.62, 128.57, 128.16, 128.11, 128.09, 127.99, 127.92, 127.81, 
127.66, 122.29, 99.41, 79.87, 79.78, 79.25, 77.67, 77.45, 77.25, 76.82, 76.47, 74.95, 74.76, 
73.81, 73.51, 73.41, 72.08, 70.17, 50.28, 36.87, 32.16, 31.75, 30.43, 30.08, 29.96, 29.94, 
29.91, 29.89, 29.85, 29.70, 29.61, 29.59, 26.06, 25.88, 25.52, 22.92, 22.55, 14.35, 14.05. 
Exact mass (ESI-MS) for C91H138N4O8 [M+H]
+
 found, 1416.0526; calcd, 1416.0593. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-6-(4-phenyltriazol-1-yl)-α-D-
galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (8c). 
1
H NMR (300 MHz, CDCl3): δ7.93-7.72 (m, 3H, arom. H), 7.31-7.18 (m, 28H), 5.55 (d, J = 
8.2 Hz, 1H, NH), 4.95 (d, J = 10.9 Hz, 1H, CH2-Ph), 4.78 (app. s, 1H, H-1”), 4.73-4.55 (m, 
6H, CH2-Ph), 4.47-4.34 (m, 4H, CH2-Ph, H-6”), 4.25-4.18 (m, 2H, H-2, H-6”), 4.06-3.97 (m, 
2H, H-5”, H-2”), 3.79 (app. d, J = 10.0 Hz, 1H, H-3”), 3.69-3.52 (m, 4H, H-4”, H-3, H-1), 
12 
 
3.42-3.41 (m, 1H, H-4), 1.82-1.66 (m, 2H, COCH2), 1.49-0.99 (m, 72H, CH2), 0.80 (t, J = 6.5 
Hz, 6H, CH3).  
13
C NMR (75 MHz, CDCl3): δ173.19, 162.87, 138.76, 138.68, 138.58, 138.51, 138.48, 
130.85, 129.03, 128.82, 128.69, 128.68, 128.63, 128.58, 128.28, 128.21, 128.13, 128.01, 
127.98, 127.91, 127.81, 127.68, 125.88, 121.47, 99.69, 80.15, 79.45, 79.27, 77.70, 77.49, 
77.28, 76.86, 76.45, 75.06, 74.75, 73.80, 73.60, 73.40, 72.00, 70.10, 68.90, 50.41, 36.86, 
36.73, 32.17, 31.69, 30.50, 30.08, 29.95, 29.90, 29.84, 29.65, 29.60, 25.86, 22.93, 14.37. 
Exact mass (ESI-MS) for C93H134N4O8 [M+H]
+
 found, 1436.0295; calcd, 1436.0274, 
[M+Na]
+
 found 1458.0104; calcd, 1458.0094, [M+K]
+ 
found 1473.9843, calcd, 1473.9833. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-6-(4-benzyltriazol-1-yl)-α-D-
galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (8d) 
1
H NMR (300 MHz, CDCl3): δ7.30-7.09 (m, 31H, arom. H), 5.63 (d, J =8.6 Hz, 1H, NH), 
4.92 (d, J = 11.1 Hz, 1H, CH2-Ph), 4.74 (d, J = 2.9 Hz, 1H, H-1”), 4.70 (d, J = 11.8 Hz, 1H, 
CH2-Ph), 4.69 (d, J = 13.0 Hz, 1H, CH2-Ph), 4.66 (d, J = 12.1 Hz, 1H, CH2-Ph), 4.64 (d, J = 
11.6 Hz, 1H, CH2-Ph), 4.56 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.50 (d, J = 11.1 Hz, 1H, CH2-Ph), 
4.48 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.39 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.38 (d, J = 11.6 Hz, 
1H, CH2-Ph), 4.25 (dd, J = 5.6 and 13.8 Hz, 1H, H-6”), 4.16-4.09 (m, 2H, H-2, H-6”), 3.98-
3.93 (m, 4H, CH2-Ph, H-2”, H-5”), 3.79 (dd, J = 2.4 and 10.1 Hz, 1H, H-3”), 3.68 (app. s, 1H, 
H-4”), 3.64 (dd, J = 3.5 and 5.7 Hz, 1H, H-3), 3.55 (dd, J = 6.1 and 10.7 Hz, 1H, H-1), 3.45-
3.38 (m, 2H, H-4, H-1), 1.89-1.70 (m, 2H, COCH2), 1.54-1.18 (m, 72H, CH2), 0.80 (t, J = 6.7 
Hz, 6H, CH3). 
13
C NMR (75 MHz, CDCl3): δ172.98, 147.54, 139.32, 138.82, 138.53, 138.46, 138.34, 
128.85, 128.83, 128.71, 128.69, 128.64, 128.62, 128.58, 128.17, 128.11, 128.06, 128.04, 
128.00, 127.95, 127.88, 127.81, 127.68, 126.97, 123.19, 99.27, 79.97, 79.58, 79.21, 77.67, 
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77.45, 77.25, 76.83, 76.42, 74.90, 74.71, 73.82, 73.49, 73.39, 72.04, 70.06, 68.41, 50.52, 
50.17, 36.89, 32.38, 32.16, 30.34, 30.10, 29.97, 29.94, 29.89, 29.86, 29.71, 29.61, 29.60, 
26.11, 25.90, 22.93, 14.36. 
Exact mass (ESI-MS) for C94H136N4O8 [M+H]
+
 found, 1450.0453; calcd, 1450.0431, 
[M+Na]
+
 found 1472.0304; calcd, 1472.0250. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-6-(4-ethylphenyltriazol-1-
yl)-α-D-galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (8e). 
1
H NMR (300 MHz, CDCl3): δ7.30-7.06 (m, 31H, arom. H), 5.64 (d, J = 8.5 Hz, 1H, NH), 
4.93 (d, J = 11.3 Hz, 1H, CH2-Ph), 4.77 (d, J = 3.7 Hz, 1H, H-1”), 4.73-4.62 (m, 3H, CH2-
Ph), 4.57 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.52 (d, J = 9.2 Hz, 1H, CH2-Ph), 4.48 (d, J = 9.6 Hz, 
1H, CH2-Ph), 4.40 (d, J = 11.5 Hz, 1H, CH2-Ph), 4.39 (d, J = 11.5 Hz, 1H, CH2-Ph), 4.29 (dd, 
J = 5.92 and 13.7 Hz, 1H, H-6”), 4.22-4.15 (1H, H-2), 4.14 (dd, J = 6.7 and 13.9 Hz, 1H, H-
6”), 4.01-3.95 (m, 2H, H-2”, H-5”), 3.79 (dd, J = 2.6 and 10.2 Hz, 1H, H-3”), 3.65-3.57 (m, 
3H, H-4”, H-3, H-1), 3.51-3.41 (m, 2H, H-1, H-4), 2.96-2.82 (m, 4H, CH2-CH2-Ph), 1.88-1.70 
(m, 2H, COCH2), 1.53-1.04 (m, 72H, CH2), 0.81 (t, J = 6.7 Hz, 6H, CH3). 
13
C NMR (75 MHz, CDCl3): δ173.04, 147.29, 141.38, 138.80, 138.76, 138.56, 138.48, 
138.41, 128.76, 128.69, 128.66, 128.61, 128.58, 128.17, 128.11, 128.09, 128.01, 127.93, 
127.82, 127.65, 126.31, 122.61, 99.37, 79.84, 79.25, 77.67, 77.45, 77.25, 76.83, 76.48, 74.93, 
74.71, 73.82, 73.54, 73.42, 72.08, 70.09, 68.50, 50.36, 50.28, 36.88, 35.71, 32.16, 30.45, 
30.08, 29.96, 29.89, 29.86, 29.70, 29.61, 29.59, 27.61, 26.05, 25.89, 22.93, 21.28, 14.43, 
14.36. 
Exact mass (ESI-MS) for C95H138N4O8 [M+H]
+
 found, 1464.0540; calcd, 1464.0593. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-6-(4-propylphenyltriazol-1-
yl)-α-D-galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (8f). 
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1
H NMR (300 MHz, CDCl3): δ7.36-7.17 (m, 31H, arom. H), 5.73 (d, J = 8.5 Hz, 1H, NH), 
5.03 (d, J = 11.9 Hz, 1H, CH2-Ph), 4.87 (d, J = 3.5 Hz, 1H, H-1”), 4.82 (d, J =11.8 Hz, 1H, 
CH2-Ph), 4.80 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.73 (d, J = 12.0 Hz, 2H, CH2-Ph), 4.66 (d, J = 
11.8 Hz, 1H, CH2-Ph), 4.65 (d, J = 11.27 Hz, 1H, CH2-Ph), 4.57 (d, J = 11.6 Hz, 1H, CH2-
Ph), 4.49 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.47 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.40 (dd, J = 6.0 
and 13.8 Hz, 1H, H-6”), 4.32-4.20 (m, 2H, H-2, H-6”), 4.11-4.05 (m, 2H, H-5”, H-2”), 3.89 
(dd, J = 2.6 and 10.0 Hz, 1H, H-3”), 3.76 (app. d, J = 1.5 Hz, 1H, H-4”), 3.74-3.66 (m, 2H, H-
3, H-1), 3.59 (dd, J = 4.6 and 10.7 Hz, 1H, H-1), 3.54-3.50 (m, 1H, H-4), 2.77-2.64 (m, 4H, 
CH2-CH2-Ph), 2.05-1.81 (m, 4H, CH2, CH2, COCH2), 1.61-1.28 (m, 72H, CH2), 0.90 (t, J = 
6.7 Hz, 6H, CH3). 
13
C NMR (75 MHz, CDCl3): δ173.04, 147.93, 142.09, 138.84, 138.79, 138.57, 138.51, 
138.44, 128.79, 128.76, 128.72, 128.70, 128.66, 128.64, 128.61, 128.58, 128.18, 128.13, 
128.10, 128.02, 127.94, 127.83, 127.68, 126.17, 126.07, 122.41, 99.43, 79.80, 79.26, 77.73, 
77.30, 76.88, 76.50, 74.96, 74.75, 73.84, 73.54, 73.44, 72.08, 70.15, 68.94, 50.31, 36.88, 
35.65, 34.87, 32.18, 31.29, 30.42, 30.30, 30.09, 29.98, 29.96, 29.94, 29.91, 29.87, 29.72, 
29.63, 26.06, 25.91, 25.39, 22.95, 18.06, 14.38. 
Exact mass (ESI-MS) for C96H140N4O8 [M+H]
+
 found, 1478.0772; calcd, 1478,0749. 
(2S,3S,4R)-3,4-di-O-benzyl-1-O-(2,3,4-tri-O-benzyl-6-deoxy-6-(triazol-1-yl)-α-D-
galactopyranosyl)-2-hexacosylamino-octadecane-1,3,4-triol (8a). 
Azide 7 was dissolved in vinyl acetate and stirred at 120 °C in the microwave. After 6 h, the 
reaction mixture was evaporated to dryness. Purification by column chromatography 
(hexanes/EtOAc: 7.5/2.5) afforded the desired triazole 8a (93 mg, 71%). 
1
H NMR (300 MHz, CDCl3): δ 7.53 (dd, J = 0.9 and 7.3 Hz, 2H, arom. H), 7.36-7.22 (m, 
25H, arom. H), 5.68 (d, J = 8.5 Hz, 1H, NH), 5.01 (d, J = 11.2 Hz, 1H, CH2-Ph), 4.84 (d, J = 
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3.6 Hz, 1H, H-1”), 4.80 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.78 (d, J = 11.8 Hz, 1H, CH2-Ph), 
4.71 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.70 (d, J = 11.7 Hz, 1H, CH2-Ph), 4.64 (d, J = 11.7 Hz, 
1H, CH2-Ph), 4.63 (d, J = 11.2 Hz, 1H, CH2-Ph), 4.55 (d, J = 11.6 Hz, 1H, CH2-Ph), 4.47 (d, J 
= 11.8 Hz, 1H, CH2-Ph), 4.45 (d, J = 11.8 Hz, 1H, CH2-Ph), 4.39 (dd, J = 5.2 and 13.9 Hz, 
1H, H-6”), 4.29 (d, J = 7.7 and 13.9 Hz, 1H, H-6”), 4.23-4.17 (m, 1H, H-2), 4.07-4.01 (m, 2H, 
H-2”, H-5”), 3.87 (dd, J = 2.6 and 10.1 Hz, 1H, H-3”), 3.77 (app. d, J = 1.3 Hz, 1H, H-4”), 
3.68 (dd, J = 3.6 and 5.2 Hz, 1H, H-3), 3.62 (dd, J = 6.9 and 10.6 Hz, 1H, H-1), 3.55-3.47 (m, 
2H, H-1, H-4), 1.95-1.77 (m, 2H, COCH2), 1.61-1.13 (m, 72H, CH2), 0.88 (t, J = 6.7 Hz, 6H, 
CH3). 
13
C NMR (75 MHz, CDCl3): δ172.95, 149.61, 138.59, 138.49, 138.33, 138.27, 138.08, 
133.65, 128.57, 128.51, 128.48, 128.45, 128.41, 128.37, 128.03, 127.89, 127.88, 127.85, 
127.79, 127.73, 127.62, 127.47, 124.77, 116.19, 99.01, 79.69, 79.61, 78.96, 76.25, 74.73, 
74.63, 73.58, 73.38, 73.11, 71.96, 69.94, 50.40, 50.04, 36.69, 31.94, 30.28, 29.83, 29.74, 
29.69, 29.67, 29.62, 29.46, 29.39, 29.37, 25.86, 25.67, 22.70, 14.13. 
Exact mass (ESI-MS) for C87H130N4O8 [M+H]
+
 found, 1359.9907; calcd, 1359.9967, 
[M+Na]
+
 found, 1381.9797; calcd, 1381.9786. 
General procedure for debenzylation 
A solution of the protected triazole (0.06 mmol) in CHCl3 (0.4 mL) and EtOH (1.2 mL) was 
hydrogenated under atmospheric pressure in the presence of palladium black (10 mg). Upon 
reaction completion, the mixture was diluted with pyridine and filtered through celite. The 
filter cake was rinsed with CHCl3 and EtOH and the filtrate was evaporated to dryness. After 
purification by column chromatography (CH2Cl2/MeOH: 8/2), final compounds 9a (31%), 9b 
(50%), 9c (40%), 9d (22%), 9e (31%) and 9f (53%) were obtained as white powders. 
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(2S,3S,4R)-1-O-(6-deoxy-6-(triazol-1-yl)-α-D-galactopyranosyl)-2-hexacosylamino-
octadecane-1,3,4-triol (9a). 
1
H NMR (300 MHz, pyridine-d5): δ8.42 (d, J = 8.9 Hz, 1H, NH), 8.21 (d, J = 0.9 Hz, 1H, 
arom. H), 7.92 (d, J = 0.9 Hz, 1H, arom. H), 5.5 (d, J = 3.7 Hz, 1H, H-1”), 5.26-5.19 (m, 1H, 
H-2), 5.14-4.99 (m, 2H, H-6”), 4.67-4.61 (m, 2H, H-2”, H-5”), 4.38-4.30 (3H, H-1, H-3”, H-
3), 4.26-4.21 (m, 2H, H-4, H-4”), 4.09 (dd, J = 4.9 Hz and 10.6 Hz, 1H, H-1), 2.50-2.36 (m, 
2H, COCH2), 2.01-1.09 (m, 72H, CH2), 0.88 (t, J = 6.7 Hz, 6H, CH3). 
13
C NMR (75 MHz, pyridine-d5): δ 171.92, 149.07, 148.72, 148.36, 147.99, 135.00, 134.66, 
134.33, 134.00, 133.64, 132.60, 124.24, 122.98, 122.65, 122.32, 121.99, 121.61, 99.98, 75.54, 
71.23, 69.78, 69.67, 69.47, 68.57, 67.06, 50.30, 49.77, 35.57, 33.34, 30.94, 29.21, 28.97, 
28.86, 28.83, 28.75, 28.69, 28.63, 28.58, 28.43, 25.27, 25.20, 21.76, 13.10. 
IR: 3462, 3451, 3335, 2922, 2850, 1653. 
Exact mass (ESI-MS) for C52H100N4O8[M+H]
+
 found, 909.7681; calcd, 909.7619, [M+Na]+ 
found, 931.7450; calcd, 931.7439. 
(2S,3S,4R)-1-O-(6-deoxy-6-(4-butyltriazol-1-yl)-α-D-galactopyranosyl)-2-
hexacosylamino-octadecane-1,3,4-triol (9b). 
1
H NMR (300 MHz, pyridine-d5): δ 8.42 (d, J = 8.7 Hz, 1H, NH), 7.93 (s, 1H, arom. H), 6.83 
(br. s, 1H, OH), 6.37 (br. s, 1H, OH), 6.05 (br. s, 1H, OH), 5.52 (d, J = 3.9 Hz, 1H, H-1”), 
5.26-5.19 (m, 1H, H-2), 5.03 (app. d, J = 6.5 Hz, 2H, H-6”), 4.70-4.62 (m, 2H, H-5”, H-2”), 
4.41 (dd, J = 5.4 and 10.7 Hz, 1H, H-1), 4.32 (dd, J = 3.2 and 9.9 Hz, 1H, H-3”), 4.27-4.22 
(m, 3H, H-3, H-4”, H-4), 4.16 (dd, J = 4.9 and 10.6 Hz, 1H, H-1), 2.83 (t, J = 7.6 Hz, 2H, 
CH2), 2.48-2.39 (m, 2H, COCH2), 1.94-1.11 (m, 76H, CH2), 0.93-0.86 (m, 9H, CH3). 
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13
C NMR (75 MHz, pyridine-d5): δ 171.94, 100.11, 75.56, 71.24, 69.83, 69.72, 69.41, 68.62, 
67.25, 50.21, 49.90, 35.58, 33.32, 30.94, 30.81, 29.24, 28.98, 28.86, 28.83, 28.75, 28.74, 
28.71, 28.64, 28.61, 28.44, 28.43, 25.29, 25.21, 24.59, 21.76, 21.39, 13.10, 12.82. 
Exact mass (ESI-MS) for C56H108N4O8 [M+H]
+
 found, 965.8295; calcd, 965.8240, [M+Na]
+
 
found, 987.8087; calcd, 987.8059, [M+K]
+
 found, 1003.7825; calcd, 1003.7799. 
(2S,3S,4R)-1-O-(6-deoxy-6-(4-phenyltriazol-1-yl)-α-D-galactopyranosyl)-2-
hexacosylamino-octadecane-1,3,4-triol (9c). 
1
H NMR (300 MHz, pyridine-d5): δ8.66 (s, 1H, arom. H), 8.40 (d, J = 8.7 Hz, 1H, NH), 8.21-
8.18 (m, 2H, arom. H), 7.50-7.45 (m, 2H, arom. H), 7.38-7.33 (m, 1H, arom. H), 5.55 (d, J = 
3.7 Hz, 1H, H-1”), 5.28-5.19 (m, 1H, H-2), 5.10 (app. d, J = 5.5 Hz, 2H, H-6”), 4.75 (t, J = 
6.6 Hz, 1H, H-5”), 4.66 (dd, J = 3.7 and 9.8 Hz, 1H, H-2”), 4.45 (dd, J = 5.6 and 10.6 Hz, 1H, 
H-1), 4.35 (dd, J = 3.2 and 9.9 Hz, 1H, H-3”), 4.27-4.22 (m, 3H, H-3, H-4, H-4”), 4.15 (dd, J 
= 4.9 and 10.8 Hz, 1H, H-1), 2.45-2.22 (m, 2H, COCH2), 1.90-1.17 (m, 72H, CH2), 0.88 (t, J 
= 6.7 Hz, 6H, CH3). 
13
C NMR (75 MHz, pyridine-d5): δ 171.95, 149.40, 149.07, 148.71, 148.35, 146.54, 134.66, 
134.33, 134.00, 130.91, 128.07, 126.94, 124.95, 122.99, 122.66, 122.33, 122.00, 121.60, 
121.01, 100.05, 75.56, 71.22, 69.79, 69.54, 69.25, 68.60, 67.07, 50.34, 49.83, 35.54, 33.32, 
30.94, 29.23, 28.97, 28.87, 28.83, 28.75, 28.74, 28.70, 28.61, 28.58, 28.44, 28.43, 25.26, 
25.18, 21.76, 13.10. 
Exact mass (ESI-MS) for C58H104N4O8 [M+H]
+
 found, 985.7953; calcd, 985.7927, [M+Na]
+
 
found, 1007.7729; calcd, 1007.7746. 
(2S,3S,4R)-1-O-(6-deoxy-6-(4-benzyltriazol-1-yl)-α-D-galactopyranosyl)-2-
hexacosylamino-octadecane-1,3,4-triol (9d) 
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1
H NMR (300 MHz, pyridine-d5): δ 8.41 (d, J = 8.7 Hz, 1H, NH), 7.91 (s, 1H, arom. H), 7.47-
7.45 (m, 2H, arom. H), 7.41-7.36 (m, 2H, arom. H), 7.28-7.26 (m, 1H, arom. H), 5.48 (d, J = 
3.7 Hz, 1H, H-1”), 5.23-5.19 (m, 1H, H-2), 5.01-4.99 (m, 2H, H-6”), 4.64-4.59 (m, 2H, H-2”, 
H-5”), 4.36 (dd, J = 5.2 and 10.7 Hz, 1H, H-1), 4.32-4.25 (m, 3H, H-4, H-4”, H-3, CH2-Ph), 
4.21 (app. d, J = 2.4 Hz, 1H, H-3”), 4.14 (dd, J = 4.6 and 10.7 Hz, 1H, H-1), 2.48-2.41 (m, 
2H, COCH2), 1.93-1.26 (m, 72H, CH2), 0.88 (t, J = 6.6 Hz, 6H, CH3). 
13
C NMR (75 MHz, pyridine-d5): δ 171.92, 149.06, 148.70, 148.35, 147.98, 146.06, 139.26, 
135.00, 134.66, 134.33, 133.99, 133.64, 128.02, 127.78, 125.45, 122.98, 122.65, 122.32, 
122.20, 121.99, 100.13, 75.55, 71.30, 69.79, 69.71, 69.47, 68.56, 67.44, 50.37, 49.83, 35.58, 
33.29, 31.33, 30.95, 29.24, 28.98, 28.87, 28.83, 28.75, 28.74, 28.71, 28.64, 28.61, 28.55, 
28.44, 28.43, 28.37, 25.31, 25.22, 21.76, 13.10. 
Exact mass (ESI-MS) for C59H106N4O8 [M+H]
+
 found, 999.8134; calcd, 999.8089, [M+Na]
+
 
found, 1021.7906; calcd, 1021.7908, [M+K]
+
 found, 1037.7676; calcd, 1037.7648. 
(2S,3S,4R)-1-O-(6-deoxy-6-(4-ethylphenyltriazol-1-yl)-α-D-galactopyranosyl)-2-
hexacosylamino-octadecane-1,3,4-triol (9e). 
1
H NMR (300 MHz, pyridine-d5): δ8.43 (d, J = 8.7 Hz, 1H, NH), 7.88 (s, 1H, arom. H), 7.36-
7.31 (m, 3H, arom. H), 7.27-7.25 (m, 2H, arom. H), 5.50 (d, J = 3.9 Hz, 1H, H-1”), 5.26-5.19 
(m, 1H, H-2), 5.01-4.96 (m, 2H, H-2”, H-5”), 4.67-4.61 (m, 2H, H-6”), 4.39 (dd, J = 5.3 and 
10.6 Hz, 1H, H-1), 4.61 (dd, J = 3.2 and 9.9 Hz, 1H, H-3” or H-4”) 4.56 (m, 2H, H-3, H-4), 
4.49 (app. d, J = 2.4 Hz, H-3” or H-4”), 4.15 (dd, J = 5.0 and 10.7 Hz, 1H, H-1), 3.22-3.11 
(m, 4H, CH2), 2.47-2.40 (m, 2H, COCH2), 1.94-1.24 (m, 72H, CH2), 0.89 (t, J = 6.7 Hz, 6H, 
CH3). 
13
C NMR (75 MHz, pyridine-d5): δ 173.49, 150.58, 150.21, 149.86, 147.64, 142.41, 136.17, 
135.84, 135.51, 129.24, 129.12, 126.72, 124.49, 124.16, 123.83, 123.50, 123.18, 123.12, 
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101.57, 77.11, 72.76, 71.34, 71.22, 70.91, 70.14, 51.76, 51.42, 37.10, 36.35, 34.85, 32.46, 
32.45, 30.75, 30.49, 30.38, 30.34, 30.27, 30.25, 30.21, 30.14, 30.11, 29.96, 29.94, 28.44, 
26.80, 26.72, 23.27, 14.61. 
Exact mass (ESI-MS) for C60H108N4O8 [M+H]
+
 found, 1013.8259; calcd, 1013.8240. 
(2S,3S,4R)-1-O-(6-deoxy-6-(4-propylphenyltriazol-1-yl)-α-D-galactopyranosyl)-2-
hexacosylamino-octadecane-1,3,4-triol (9f). 
1
H NMR (300 MHz, pyridine-d5): δ 8.38 (d, J = 8.7 Hz, 1H, NH), 7.93 (s, 1H, arom. H), 7.37-
7.24 (m, 5H, arom. H), 7.11 (br. s, 1H, OH), 6.94 (br. s, 1H, OH), 6.82 (d, J = 2.9 Hz, 1H, 
OH), 6.36 (d, J = 5.0 Hz, 1H, OH), 6.04 (d, J = 3.9 Hz, 1H, OH), 5.51 (d, J = 3.7 Hz, 1H, H-
1”), 5.26-5.18 (m, 1H, H-2”), 5.03 (d, J = 5.03 Hz, 2H, H-6”), 4.71-4.62 (m, H-5”, H-2”), 
4.41 (dd, J = 5.4 and 10.4 Hz, 1H, H-1), 4.33-4.20 (m, 5H, H-3”, H-3, H-4, H-4”), 4.15 (dd, J 
= 5.0 and 10.7 Hz, 1H, H-1), 2.86 (t, J = 7.6 Hz, 2H, CH2), 2.72 (t, J = 7.6 Hz, 2H, CH2), 2.41 
(ddd, J = 3.0 and 7.5 Hz, 2H, COCH2), 2.10 (quintet, J = 7.6 Hz, 2H, CH2), 1.90-1.18 (m, 
72H, CH2), 0.87 (t, J = 6.6 Hz, 6H, CH3).  
13
C NMR (75 MHz, pyridine-d5): δ 173.43, 150.58, 150.22, 149.87, 149.49, 148.06, 142.91, 
136.51, 136.17, 135.84, 135.51, 135.14, 129.33, 129.10, 126.51, 124.49, 124.16, 123.83, 
123.50, 123.10, 101.63, 77.07, 72.75, 71.34, 71.21, 70.88, 70.13, 68.79, 51.70, 51.40, 37.08, 
35.92, 34.83, 32.46, 32.45, 31.95, 30.75, 30.50, 30.38, 30.34, 30.27, 30.25, 30.22, 30.15, 
30.12, 29.96, 29.94, 26.79, 26.72, 25.92, 23.28, 14.62. 
Exact mass (ESI-MS) for C61H110N4O8 [M+H]
+
 found, 1027.8478; calcd, 1027.8402. 
Computational modeling 
The starting conformation of the triazole was generated using OpenBabel version 2.3.1
25
 and 
graphical visualisation of the complex was done with PyMol.
26
 The structure was 
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subsequently positioned into the binding pocket of Nu-α-GalCer (crystal structure was taken 
from the PDB, code 3QUZ) by superimposing the sugar ring of the triazole compound onto 
the corresponding ring of Nu-α-GalCer. Torsion angles were rotated to adopt a low energy 
conformation. 
Biological evaluation 
Lyophilized glycolipids were dissolved in pure DMSO (Sigma) at 10 mg/mL concentration 
and stored at -20˚. Glycolipids were solubilized at 100 ng/mL concentration by adding vehicle 
(96mg/mL sucrose, 10mg/mL sodium deoxycholate, 0,05% Tween 20), warming to 80°C for 
20 minutes and sonication for 10 minutes.  
For in vitro stimulation, murine iNKT hybridoma N38-2C12 (V 14V 8.1/8.2b) cells at 
5.10E4 cells/well in 96-well plates were stimulated with the 10E5 cells/well glycolipid pulsed 
BMDCs in cDMEM for 16 hours at 37˚C, and levels of murine IL-2 secretion were 
determined by ELISA. 
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